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Ginseng is among the oldest traditional Chinese medicinal herbs and is widely used in China and Southeast Asia. Over the past 
50 years, considerable research has focused on the chemical constituents, pharmacological action, and clinical applications of 
ginseng. In this review, we examine the current state of research on ginseng, including the main active ingredient ginsenoside, 
its pharmacological effects on the cardiovascular system, and mechanisms of action. We focus on what is known of the effects 
of ginseng against atherosclerosis, arrhythmia, myocardial ischemia, and its inhibition of ventricular remodeling, providing a 
basis for expanding the clinical applications of ginseng. 
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Ginseng (Panax ginseng C.A. Meyer) is a perennial herb 
originating from the Tertiary period with about 60 million 
years of history that has survived because of genetic varia-
tions incurred during the Quaternary glacial epoch. It is of-
ten referred to as a periglacial plant and living fossil, and 
enjoys a reputation as the King of Herbs. Each part of the 
ginseng plant—but particularly the root—has high medici-
nal value and is widely used in Asia. According to Shen-
nong’s Herbal Classic, ginseng is one of the popular medi-
cines for nourishing the body and can be taken over a long 
term without causing harm. Ginseng is sweet, tepid after 
processing, and non-toxic, and has an anti-aging effect ow-
ing to its ability to tonify Qi; this has been described in 
Zhang Zhongjing’s book Treatise on Cold Pathogenic and 
Miscellaneous Diseases (“Shanghan Za Bing Lun”), Li 
Shizhen’s work Compendium of Materia Medica (“Ben Cao 
Gang Mu”), and a variety of books on herbal medicine since 
the Qing Dynasty. It is also known to reinforce vital energy, 
fortify the spleen to benefit the lungs, nourish fluids, calm 
the heart, tranquilize the mind, and so on. 
In the last 50 years, there has been considerable research 
on the active ingredients, pharmacological effects, and clin-
ical applications of ginseng. The academic monograph 
Chemistry, Biological Activity and Pharmacokinetics of 
Panax ginseng Meyer (Zhang, 2012) has been updated to 
version 2 and is widely influential. Ginseng has various 
physiological effects; it is known to reduce fatigue, improve 
immunity, slow aging, inhibit cancer metastasis, regulate 
blood sugar, protect liver and kidney functions, and has 
nootropic effects, with two-way regulation of the central 
nervous system (Zhang, 1995; Chu and Zhang, 2009).  
Cardiovascular diseases account for a large percentage of 
disease-related deaths worldwide, and as such, the discov-
ery of novel drugs or compounds among traditional herbal 
medicines that have cardiovascular protective effects is a 
focus of intense research (Hao et al., 2015; Yao et al., 
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2015). Research on the cardiovascular pharmacology of 
ginseng has aroused great interest among scholars in recent 
years. The present review discusses the research carried out 
over the past decade in China and elsewhere on the main 
active ingredient of ginseng (i.e., ginsenoside), its pharma-
cological effects on cardiovascular function, and the under-
lying mechanisms of action. We specifically focus on the 
cardiovascular properties of ginseng, including its an-
ti-atherosclerotic, anti-arrhythmic, and anti-myocardial is-
chemic effects and its inhibitory effects on ventricular re-
modeling. This evidence can provide a basis for further re-
search on ginseng and expand its clinical applications. 
CHEMICAL COMPONENTS OF GINSENG 
More than 300 compounds have been isolated from ginseng. 
These include ginsenoside, the main active ingredient and 
one of more than 50 saponin monomers that influence me-
tabolism as well as immune, antioxidant, endocrine, and 
central nervous systems and are used in the treatment and 
prevention of cardiovascular diseases; as well as polysac-
charides, amino acids, proteins, carbohydrates, vitamins, 
organic acids, trace elements, and flavonoids. 
Ginsenoside is a glycoside formed by removal of a water 
molecule from the hemiacetal hydroxyl of a sugar molecule 
and a hydroxyl from non-carbohydrate compounds. Gin-
senoside differs from other saponins in terms of the ring 
structure of sapogenin. Ginsenosides can be classified into 
oleanolic acid, protopanaxadiol, and protopanaxatriol types  
based on the parent ring structure (Bai et al., 2014; Kim   
et al., 2015) (Figure 1 and Table 1). 
CARDIOVASCULAR PHARMACOLOGICAL 
EFFECTS OF GINSENOSIDE AND 
MECHANISMS OF ACTION 
Anti-atherosclerotic effects and protection of the vascu-
lar endothelium 
Coronary heart disease is among the most common diseases 
and is caused by atherosclerosis (AS)-induced endothelial 
dysfunction leading to systemic organ disease (An et al.,  
Table 1  Classification of ginsenosides 
Subtype Ginsenoside 








Oleanolic acid type Ro 
Rh3 
Ri 









Figure 1  Panax ginseng C.A. Meyer plant and chemical structures of ginsenoside subtypes. A, Illustration of Panax ginseng C.A. Meyer. B–D, Chemical 
structures of protopanaxadiol-type (B), oleanolic acid-type (C), and protopanaxatriol-type (D). 
294 Sun, Y., et al.   Sci China Life Sci   March (2016) Vol.59 No.3 
2014; Zhang and Dong, 2014), which is associated with a 
high rate of morbidity and mortality. Risk factors for coro-
nary AS include dyslipidemia, hyperglycemia, hyperten-
sion, and platelet aggregation and activation. 
Oxidized low-density lipoprotein (oxLDL) inhibits lac-
tate dehydrogenase (LDH) activity, decreases endothelial 
nitric oxide synthase (NOS) expression, and modulates tis-
sue-type plasminogen activator and plasminogen activator 
inhibitor 1 (PAI-1) activities. Studies on human umbilical 
vein endothelial cells (HUVECs) pretreated for 24 h with a 
high dose of ginsenoside Rb1 (10 mg mL1) have reported 
an inhibition of oxLDL and consequent protection of endo-
thelial cells (He et al., 2007). Hyperlipidemic rats fed gin-
senoside Rh2 (200 mg kg1 d1) for 11 weeks showed re-
duced serum LDL-C and total cholesterol (TC) levels and 
increased serum NO and superoxide dismutase activities. 
Rh2 also decreased malondialdehyde levels, reduced lipid  
peroxidation, enhanced oxygen free radical scavenging, and 
stabilized cell membranes, thereby protecting endothelial 
cells via these anti-AS effects (Kong et al., 2010).  
Similarly, hyperlipidemic rats treated with ginsenoside Rb  
(50–200 mg kg−1 d−1) for 12 d showed decreased serum TC, 
triglyceride (TG), and LDL-C levels and increased HDL-C 
level, suggesting that Rb enhanced cholesterol transport 
from peripheral tissues to the liver, which in turn reduced 
cholesterol accumulation and prevented endothelial cell 
damage and AS (Zhang et al., 2004). In a rat carotid artery 
injury model, ginsenoside Rg1 improved tissue damage 
caused by aortic injury and neointimal thickening, suggest-
ing that it can inhibit neointimal hyperplasia, possibly by 
reducing oxidative stress and stimulating NOS expression 
and NO production (Gao et al., 2012). Ginsenosides have 
also been shown to inhibit nuclear factor B signaling (Ru-
an et al., 2004) by suppressing lipopolysaccharide-induced 
PAI-1 expression, promoting fibrinolysis, and preventing 
thrombosis in HUVECs. In a spontaneously hypertensive rat 
model, Rb1 reduced blood pressure at high (60 mg kg1) 
and low (30 mg kg1) doses over a 12-week period, possibly 
via regulation of the balance between helper T17 and  
regulatory T cells (Chen et al., 2014). Rats continuously 
treated with ginsenoside Rg2 at low (2.5 mg kg1), medium 
(5.0 mg kg1), or high doses (10 mg kg1) for 3 d exhibited 
prolonged thrombosis time and a decrease in adenosine di-
phosphate (ADP)-induced platelet aggregation (Tian et al., 
2009). Similarly, in a rat model of acute blood stasis in 
which three doses of Rb (25, 50, and 100 mg kg1) were 
continuously administered for 7 d, blood viscosity, platelet 
aggregation, and blood rheology were improved, which 
prevented high-viscosity conditions in the coronary artery 
during acute myocardial infarction, thrombosis formation, 
and the occurrence and development of AS (He et al., 
2007). Rg1 has also been shown to inhibit platelet aggrega-
tion and activation induced by thrombin, ADP, collagen, 
and the thromboxane analog U46619, likely via suppression 
of the extracellular signal regulated kinase (ERK) signaling 
pathway. An inhibitory effect on thrombus formation in 
vivo has also been demonstrated (Zhou et al., 2014). Gin-
senoside Rp1 was found to inhibit platelet activation and 
thrombosis induced by collagen, which may be related to 
vasodilator-stimulated phosphoprotein activation and inhi-
bition of ERK2 and p38 mitogen-activated protein kinase 
pathways (Endale et al., 2012). 
Anti-arrhythmic effects 
Current anti-arrhythmia drugs have the side effect of ag-
gravating arrhythmias, prompting researchers to seek out 
alternative agents from herbal medicine. Ginsenosides can 
block ion channels, suggesting that they can be used to 
modulate arrhythmia (Wang et al., 2004). Three types of 
Ca2+ channel exist on the myocardial cell membrane: B 
background channels, and L- and T-type voltage-dependent 
channels. The L-type channel is the main conduit of intra-
cellular Ca2+ during cell excitation. 
Ginsenoside Rb1 treatment was found to block Ca2+ cur-
rents in a dose-dependent manner at concentrations of 
100–400 mol L1 in cardiomyocytes isolated from re-
verse-perfused guinea pig hearts using a whole-cell voltage 
clamp technique (Zeng et al., 1997). In another study using 
isolated rat ventricular myocytes perfused with Rb1  
(40 μmol L1), L-type Ca2+ currents and transient outward 
K+ currents were reduced without any alteration in channel 
kinetics (Pei et al., 2011). Ginsenoside Re administered at 
three doses (i.e., 5, 10, or 20 mg kg1) converted a triggered 
ventricular arrhythmia into a normal sinus rhythm in a rab-
bit isoproterenol-induced arrhythmia model, an effect that 
was dose-dependent. The effects of ginsenoside on hemo-
dynamics are negatively related to dosage (Chen et al., 
2009); ginseng stem leaf saponins had dose-dependent an-
tagonistic effects on chloroform-induced mouse ventricular 
cardiac arrhythmia and prevented aconitine-induced ven-
tricular arrhythmia. Chloroform improved myocardial cell 
self-regulation linked to Ca2+ influx (Tang et al., 2009). 
Ginseng stem leaf saponins were also found to suppress 
aconitine-induced rat ventricular cardiac arrhythmia, possi-
bly by modulating Na+ channel function (Xiao et al., 2013). 
Ginsenoside Re (10 or 100 mol L1) has been shown to ex-
ert anti-arrhythmic effects by inhibiting currents from ven-
tricular voltage-dependent Na+, transient outward K+, and 
inward rectifier K+ channels (Meng et al., 2013). In mice 
with toad venom-induced arrhythmia, 40 mg kg1 total gin-
senoside administration reduced the width of the QRS com-
plex and increased T-wave amplitude, thereby diminishing 
the arrhythmia and prolonging survival (Lu et al., 2012). 
Protective effects of ginsenosides against myocardial 
ischemia 
In a Langendorff isolated heart model of ischemia-   
reperfusion, 40–160 mg L1 ginsenoside pre-treatment and  
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80 mg L1 post-treatment had a protective effect against 
myocardial ischemia-reperfusion injury in rats, with greater 
effects observed with 80 mg L1 pre- and post-treatment 
doses (Li et al., 2005). Administration of total ginsenoside 
also improved myocardial ischemia-reperfusion coronary 
flow in a dose-dependent manner, which was likely associ-
ated with activation of the phosphoinositide 3-kinase/Akt- 
endothelial (e) NOS pathway and increased NO release (Yi 
et al., 2010). In addition, ischemic ventricular myocyte Ca2+ 
ion channels and Ca2+ currents were inhibited in a dose- 
dependent manner by Rb1 (100–400 μmol L1) (Zhang    
et al., 2007). Application of various doses of Rb1 in a H2O2- 
induced myocardial injury model had an anti-apoptotic ef-
fect via inhibition of lipid peroxidation and suppression of 
intracellular Ca2+ overload (Xu et al., 2005) and reactive 
oxygen species (ROS) production, which reduced oxidative 
damage and preserved mitochondrial function (Wen et al., 
2010). Rb1 was also found to inhibit ROS-induced c-Jun 
N-terminal kinase (JNK) activation (Li et al., 2012) and 
ERK signaling (Yang et al., 2014). Re and Rg1 had protec-
tive effects on 60Co irradiation-induced cardiomyocyte 
apoptosis that were exerted via attenuation of caspase 3 and 
B cell lymphoma (Bcl)-2-associated X protein (bax) expres-
sion and JNK/p38 signaling (Wu and Liu, 2008). 
Administration of various doses of Rg1 promoted the 
formation of coronary artery collaterals in a rat acute myo-
cardial infarction model, which may be associated with the 
upregulation of vascular endothelial growth factor expres-
sion and stimulation of angiogenesis (Zhang et al., 2009, 
2013; Jin et al., 2007). In a rat coronary artery liga-
tion-induced ischemia-reperfusion model, Rb1 (4 mg kg1) 
suppressed myocardial cell apoptosis (Zhang et al., 2001). 
Ginsenoside Rg3 (60 mg kg1) was also shown to have a 
protective effect on the myocardium via Akt/eNOS signal-
ing and modulation of the Bcl-2/Bax ratio (Wang et al., 
2015). In the same model, Rg1 (1–4 mg kg1) administered 
to guinea pigs in which acute myocardial ischemia was in-
duced by pituitrin showed significant improvement in elec-
trocardiogram readings as well as increased antioxidant 
enzyme activity, decreased oxidative damage from endothe-
lial cell free radicals, and a reduction in myocardial cell 
membrane damage (Lai et al., 2011). Study in rats has 
shown that the effective dose of Re for protecting against 
heart ischemia-reperfusion injury in rats (determined by 
monitoring hemodynamic parameters such as perfusion 
pressure, aortic and coronary flow, cardiac output volume, 
and left ventricular pressure) was 100 µmol L1 (Kyuhee,  
et al., 2013). Pretreatment of diabetic rats with Rb1  
(40 mg kg1 for 10 min) reduced the severity of myocardial 
ischemia-reperfusion injury, which was associated with 
increased NOS expression and NO release and suppression 
of the oxidative stress response (Xia et al., 2011). 
Inhibition of ventricular remodeling 
Ventricular remodeling refers to an increase in myocardial 
injury or ventricle load following alterations in cell size or 
shape, or ventricular wall thickness and structure. This 
phenomenon is generally associated with lesion repair and 
ventricular compensation, and is a secondary pathophysio-
logical reaction to myocardial infarction. Ventricular re-
modeling can lead to deterioration of left ventricular systol-
ic function, followed by congestive heart failure and death. 
Recent evidence suggests that ginsenoside is effective in 
mitigating this process. 
In a rat model of pressure overload-induced left ventric-
ular remodeling, continuous administration of Rb at  
25–100 mg kg1 d1 for six weeks by gavage had a protec-
tive effect against ventricular remodeling, with improved 
left ventricular systolic and diastolic functions, enhanced 
antioxidant enzyme activity, reduced myocardial damage by 
free radicals and vasoconstrictors, and a restoration of 
plasma prostacyclin prime/thromboxane A2 ratio (Wang et 
al., 2008). Left ventricular remodeling was reduced in  
rats with acute myocardial infarction by injection of Rb1  
(2 mg kg1) for four weeks, which was likely associated 
with negative regulation of the renin-angiotensin system 
(Wang et al., 2006). In neonatal rat cardiac myocytes in 
which hypertrophy was induced by angiotensin II, Rb1 
(50–200 μmol L1) suppressed the elevation in Ca2+ levels 
in a dose-dependent manner (Chen et al., 2008). Continuous 
application of Rb1 in a rat model of doxorubicin-induced 
heart failure reduced myocardial damage via modulation of 
connexin 43, which may be associated with the regulation 
of p21-activated kinase l/protein phosphatase 2A (Kong   
et al., 2013) and protein kinase RNA-like endoplasmic re-
ticulum kinase signaling (Kong et al., 2013). Furthermore, 
Rb1 (70 mg kg1 d1) used as preventive therapy for 7 mon- 
ths in cTnTR141W mice with dilated cardiomyopathy re-
sulted in an improvement in cardiac function and mitigated 
ultrastructural damage to heart tissue by reversing the dis-
ordered arrangement of myocardial cells (Zhao et al., 2009). 
Continuous application of Rg1 (5 mg kg1 d1) in rats with 
acute myocardial infarction increased the number of pe-
ripheral blood stem cells, stimulated stem cell homing to the 
infarcted myocardium, and induced myocardial regenera-
tion, thereby reducing infarct size and ventricular remodel-
ing (Yang et al., 2008). Rb1 was also shown to inhibit col-
chicine-induced right ventricular hypertrophy, which may 
be associated with suppression of calcineurin signaling 
(Jiang et al., 2007). 
Other beneficial effects of ginsenosides 
In addition to the effects described above, ginsenosides 
have demonstrated protective effects against cardiac toxicity 
during cardiac surgery. In one study in which ginsenoside 
Rd (30 mg kg1) followed by bupivacaine (2 mg kg1 min1) 
was injected into rats for 30 min, a significant improvement 
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in blood oxygen level and saturation was observed, sug-
gesting that ginsenoside pretreatment can increase survival 
rate in cases of cardiac toxicity caused by local anesthetics 
(Sun et al., 2010). A ginsenoside mixture (1.35 mg kg1) 
was reported to reduce gastrointestinal mucosal injury and 
inflammation caused by treatment of congenital heart dis-
ease in children (Xia et al., 2005). In addition, in vitro study 
has shown that the toxicity of aconitum to myocardial cells 
can be mitigated by co-administration with ginseng at a 
ratio of 1:0.5 (Wang et al., 2015). Another study reported 
that Rg3 protects vascular endothelial cells via a mechanism 
involving estrogen receptor that is similar to the effects of 
17--estradiol (Pan et al., 2014). 
CONCLUDING REMARKS AND FUTURE 
PERSPECTIVES 
Studies of the mechanisms of cardiovascular protection by 
ginseng have mostly focused on the action of ginsenosides 
(Figure 2), and there are a variety of patented Chinese med-
icines (ginseng preparations) that are used to treat cardio-
vascular diseases (Table 2). The pharmacological effects of 
other ginseng components are rarely addressed (Im and 
Nah, 2013). Ginseng holds great promise for the treatment 
of cardiovascular diseases, with many potential applica-
tions. Based on its cardiovascular pharmacological effects, 
clinicians should pay close attention to the combinations of 
drugs that are used with ginseng. There are reports of 
co-injecting ShenFu (a ginsenoside compound) with statins 
to treat non-ischemic heart failure (Zheng et al., 2010), do-
pamine to reduce recovery time of in cases of shock (Xu 
and Xu, 2012), metoprolol to treat coronary heart disease 
and heart failure (Yang and Lin, 2011), and trimetazidine to 
treat dilated cardiomyopathic heart failure (Yu et al., 2013). 
However, large, randomized, controlled, double blind clini-
cal trials are needed to verify the clinical efficacy of these 
combinations, in addition to a more detailed analysis of the 
mechanisms of action. Despite the large number of products 
made from ginseng extract, there are no strict monitoring 
standards for their production, use, and quality control. The 
main method for extracting ginseng uses ethanol, followed 
by concentration and drying. However, due to the variety of 
purification methods adopted by different manufacturers, 
 
 
Figure 2  Putative mechanisms underlying cardiovascular protective effects of ginsenosides. 
Table 2  Ingredients of frequently used patented Chinese medicines (ginseng preparations) for cardiovascular diseases 
No. 
Trade names of ginseng 
preparations 
Ingredients Types of ginsenoside References 
1 Zhenyuan capsule 
Total saponins in the fruit of Panax ginseng 
C. A. Meyer 
Ginsenoside Re (Zhao, 2014) 
2 Xinyue capsule Panax quinquefolium saponin Ginsenoside Rg1, Re, and Rb3 (Yang et al., 2013) 
3 Shenmai injection Red ginseng and Radix ophiopogonis Ginsenoside Rg1 and Re (Cao et al., 2011) 
4 Shengmai injection 
Red ginseng, Radix ophiopogonis, and 
Schisandra chinensis Ginsenoside Rb1 and Rc (Lu et al., 2011) 
5 Shenfu injection Red ginseng and Aconitum carmichaelii Ginsenoside Rd, Rb1, Rb2, Rc, 
Rg1, and Ro 
(He et al., 2014) 
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ginseng extracts differ significantly in terms of their proper- 
ties, active ingredient content, and efficacy. Hence, to fully 
exploit the medicinal properties of ginseng and its extracts 
in the treatment of vascular diseases, production and moni-
toring systems must be improved. On the other hand, re-
search on the possible toxicity of ginseng cannot be ex-
cluded; some studies have reported that Rb1 causes abnor-
malities in rat embryos (Chan, et al., 2003), which have 
aroused interest in exploring potential adverse effects of 
ginseng on development (Liu et al., 2005). Therefore, future 
research should not be confined to the benefits of ginseng 
and its preparations, and should be extended to a clarifica-
tion of their mechanisms. With ongoing research on this 
versatile compound, more effective products will undoubt-
edly be developed for much-needed prevention and treat-
ment of cardiovascular diseases. 
Compliance and ethics  The author(s) declare that they have no conflict 
of interest. 
Acknowledgements  This work was supported by the National Natural 
Science Foundation of China (81403266) and the Sponsored Project from 
Advisor of Beijing Outstanding Doctorate Dissertation (20138450201). 
An, G., Ren, G., An, F., and Zhang, C. (2014). Role of C5a-C5aR axis in 
the development of atherosclerosis. Sci China Life Sci 57, 790–794. 
Bai, M., Mao, Q., Xu, J., Zhu, L., Zhu, H., Wang, Q., and Li, S. (2014). 
Advance in saponins of aerial parts of Panax species (in Chinese). Chin 
J Chin Mater Med 39, 412–422. 
Cao, S., Nie, L., Wang, G., and Lin, R. (2011). HPLC simultaneous deter-
mination of nine ginsenosides in Shenmai injection (in Chinese). J 
Pharm Anal 31, 476–478. 
Chan, L.Y., Chiu, P.Y., and Lau, T.K. (2003). An in-vitro study of gin-
senoside Rb1-induced teratogenicity using a whole rat embryo culture 
model. Hum Reprod 18, 2166–2168.  
Chen, C., and Zhang, H. (2009). Effect of ginsenoside Re on triggering 
ventricular arrhythmia in rabbits (in Chinese). J Prac Med 25, 
2237–2240. 
Chen, M., Shi, G., Huang, Z., Li, Y., Sun, H., and Li, W. (2014). Phama-
cological effects of ginsenoside Rb1 on balance of Th17/Treg cell in 
spontaneously hypertension rats (in Chinese). Guangming J Chin Med 
29, 2534–2538. 
Chen, X., Huang, X., and Wu, Q. (2008). Ginsenoside Rb1 inhabits car-
diomyocyte hypertrophy induced by angiotensin II (in Chinese). J 
Zunyi Med Univ 31, 457–460. 
Chu, S., and Zhang, J. (2009). New achievements in ginseng research and 
its future prospects. Chin J Integr Med 15, 403–408.  
Endale, M., Lee, W.M., Kamruzzaman, S.M., Kim, S.D., Park, J.Y., Park, 
M.H., Park, T.Y., Park, H.J., Cho, J.Y., and Rhee, M.H. (2012). Gin-
senoside-Rp1 inhibits platelet activation and thrombus formation via 
impaired glycoprotein VI signaling pathway, tyrosine phosphorylation 
and MAPK activation. Br J Pharmacol 167, 109–127. 
Gao, Y., Wu, Q., Yang, D., Deng, J., and Huang, X. (2012). Inhibitory 
effect of ginsenoside Rg1 on vascular neointimalhyperplasiainduced by 
balloon-injury in rats and the relation to its anti-oxidantaction and 
up-regulating of eNOS expression (in Chinese). Chin Pharmacol Bull, 
28, 388–392. 
Hao, P., Jiang. F., Chen, Y., Yang, J., Zhang, K., Zhang, M., Zhang, C., 
Zhao, Y., and Zhang, Y. (2015). Traditional Chinese medication for 
cardiovascular disease. Nat Rev Cardiol 12, 115–122. 
He, F., Guo, R., Wu, S., Sun, M., and Li, M. (2007). Protective effects of 
ginsenoside Rb1 on human umbilical vein endothelial cells in vitro. J 
Cardiovasc Pharmacol 50, 314–320. 
He, J., Zhou, S., Ma, Z., Liang, Q., Wang, Y., Tan. H., Xiao, C., Tang, X., 
and GAO, Y. (2014). Material basis of Shenfu injection based on 
UPLC-Q-TOF/MS (in Chinese). Chin Pharmacol Bull 30, 429–433. 
He, X., Xu, H., Yu, X., Qu, S., and Sui, D. (2007). Effects of Ginseno-
side-Rb on platelet aggregation and hemorheology in rats of acute 
blood stasis model (in Chinese). Chin Pharmacol Bull 23, 1259–1260. 
Im, D.S., and Nah, S.Y. (2013). Yin and Yang of ginseng pharmacology: 
ginsenosides vs gintonin. Acta Pharmacol Sin 34, 1367–1373. 
Jiang, Q., Huang, X., Dai, Z., Yang, G., Zhou, Q., Shi, J., and Wu, Q. 
(2007). Inhibitory effect of ginsenoside Rb1 on cardiac hypertrophy 
induced by monocrotalinein rat. J Ethnopharmacol 111, 567–572. 
Jin, Y., and Liu, G. (2007). Effects of ginsenoside Rg1 on angiogenesis and 
VEGF expression in rats with acute myocardial infarction (in Chinese). 
J Chin Med Univ 36, 517–519. 
Kim, Y.J., Zhang, D., and Yang, D.C. (2015). Biosynthesis and biotechno-
logical production of ginsenosides. Biotechnol Adv 33, 717–735. 
Kong, F., Sun, X., Zhao, X., and Li, Y. (2010). Experimental studies an-
ti-atherosclerotic effects and mechanisms of ginsenoside Rh2 (in Chi-
nese). J Beihua Univ (Nat Sci) 11, 520–523. 
Kong, H., Hou, A., Guo, C., and Wang, J. (2013). Influence of ginseno-
sides Rb1 on adriamycin-induced heart failure by adjusting the protein 
kinase R-like ER kinase pathway (in Chinese). Chin J Histoch Sytoch 
22, 290–295.  
Kong, H., Li, Z., Miao, Z., and Ye, L. (2013). Effects of ginesenosides-Rb1 
on connexin 43 in heart failure in rats (in Chinese). Tianjin Med J 41, 
675–678. 
KyuHee, L., Dae-Jun, L., and Jong-Hoon, K. (2013). Ginsenoside-Re ame-
liorates ischemia and reperfusion injury in the heart: a hemodynamics 
approach. J Ginseng Res 37, 283–292. 
Lai, F., Pan, Y., Ai, X., Jia, L., Zhu, K., Yang, Y., and Chen, M. (2011). 
Protective effect of ginsenoside Rg1 on acute myocardial ischemia in 
guinea pigs (in Chinese). Tradit Chin Drug Res Clin Pharmacol 22, 
390–393. 
Li, J., Shao, Z., Xie, J., Wang, C., Ramachandran, S., Yin, J., Aung, H., Li, 
C., Qin, G., VandenHoek, T. and Yuan, C. (2012). The effects of gin-
senoside Rb1 on JNK in oxidative injury in cardiomyocytes. Arch 
Pharm Res 35, 1259–1267. 
Li, J., Zhu, S., and Zeng, Y. (2005). Protective effects of different concen-
trations of ginsenoside on isolated heart ischemia reperfusion injury in 
rats (in Chinese). Chin J Anesth 25, 618–620. 
Liu, P., Xu, Y., Yin, H., Zhang, Z., Wang, J., Chen, K., and Li, Y. (2005). 
Effects of ginsenoside Rb1 on mouse embryonic development in vitro 
(in Chinese). J Hygiene Res 34, 175–177. 
Lu, J., Li, X., Wei, W., Yang, R., Zhang, P., Yao, H., and Jin, Y. (2011). 
RP-HPLC determination of seven ginsenosides in Shenmai injection (in 
Chinese). J Pharm Anal 31, 2302–2304. 
Lu, W., Zhou, J., Ma, H., Lv, G., You, F., and Ding, A. (2012). Effects of 
astragaloside Ⅳ, ginsenoside and total saponins of panaxquinquefoli-
um on mice with arrhythmia caused by toad venom (in Chinese). J 
Nanjing Univ Tradit Chin Med 28, 61–64. 
Meng, H., Yao, M., and Liu, J. (2013). Effects of ginsenoside Re on sodi-
um and potassium current in rat ventricular myocytes (in Chinese). 
World Chin Med 8, 1147–1149. 
Pan, Y., Guo, C., Ma, X., Wang, J., Liu, X., Sun, M., Zhang, M., and Yin, 
H. (2014). The estrogen-like protective effect of ginsenoside Rb3 on 
oxidative stress and dysfunction of endothelial cells induced by oxi-
dized low-density lipoprotein (in Chinese). Acta Pharma Sin 49, 
1406–1412. 
Pei, J., Zhang, Y., Chen, J., Huang, J., and Pu, J. (2011). Electrophysiolog-
ical effect of ginsenoside Rb1 on L-type calcium current and transient 
outward potassium current in isolated rat ventricular myocytes (in Chi-
nese). Mol Cardiol China 11, 230–234. 
Ruan, Q., Song, J., and Deng, Z. (2004). Effects of ginsenosides on lipo-
polysaccharide-induced plasminogen activator inhibitor type-1 and 
NF-kappa B expression in vascular endothelial cells (in Chinese). Chin 
J Cardiol 32, 351–354. 
Sun, L., Yang, S., Wang, Q., Zhu, X., and Xiong, L. (2010). Effect of 
298 Sun, Y., et al.   Sci China Life Sci   March (2016) Vol.59 No.3 
ginsenoside Rd injection on the central and cardiac toxicity of bupiva-
caine in rats (in Chinese). Chin Heart J 22, 824–827. 
Tang, Z., Tang, T., Fu, L., Tang, Y., Xiang, Y., Fan, H., and Lin, Y. 
(2009). Effects of ginseng stem leaf glucoside on mouse arrhythmia and 
death time (in Chinese). Lab Animal Sci 26, 4–7. 
Tian, J., Song, L., Li, H., Ye, J., and Li, Y. (2009). Effects of thrombosis 
and platelet aggregation of ginsenosides Rg2 in rats (in Chinese). 
Shanghai J Tradit Chin Med 43, 79–80. 
Wang, T., and Zhang, H. (2004). Review of anti-arrhythmic effects in 
Ginseng (in Chinese). Chin J Cardiac Pacing Electrophysiol 18, 
309–310. 
Wang, T., Yu, X., Qu, S., Xu, H., Han, D., and Sui, D. (2008). Effects of 
Ginsenoside Rb on ventricular remodeling in rats with pressure over-
loaded hypertrophic myocardium and its mechanism (in Chinese). 
Lishizhen Med Mater Med Res 19, 1615–1617. 
Wang, W., Zhao, L., Wang, L., Li, P., and Liu, Z. (2006). Effects of gin-
senosid Rb1 on left ventricular remodeling after myocardial infarction 
in rats (in Chinese). J Chin Microcirc 10, 256–258. 
Wang, X., Li, L., Li, Y., Li, C., and Zhang, D. (2015). Toxicity-reducing 
effect of compatibility of aconiti lateralis radix praeparata with different 
proportion of panax ginseng in neonatal Rat cardiomyocytes (in Chi-
nese). Chin J Exp Tradit Med Form 21, 153–158. 
Wang, Y., Hu, Z., Sun, B., Xu, J., Jiang, J., and Luo, M. (2015). Ginseno-
side Rg3 attenuates myocardial ischemia/reperfusion injury via 
Akt/endothelial nitric oxide synthase signaling and the B-cell lympho-
ma/B-cell Lymphoma-associated X protein pathway. Mol Med Rep 11, 
4518–4524. 
Wen, F., Zhang, F., and Leng, Q. (2010). Protective effect of ginsenoside 
Rb1 on the apoptosis of cardiomyocytes induced by hydrogen peroxide 
(in Chinese). Hubei J Tradit Chin Med 32, 5–7. 
Wu, J., and Liu, Y. (2008). Protective effect of ginsenoside Re on apopto-
sis of myocardial cells induced by 60Co irradiation (in Chinese). Chin J 
Integr Med Cardio/Cerebro Dis 6, 923–924. 
Xia, R., Zhao, B., Wu, Y., Hou, J., Zhang, L., Xu, J., and Xia, Z. (2011). 
Ginsenoside Rb1 preconditioning enhances enos expression and attenu-
ates myocardial ischemia/reperfusion injury in diabetic rats (in Chi-
nese). J Biomed Biotechnol 2011, 767930.  
Xia, Z., Liu, X., Zhan, L., He, Y., Luo, T., and Xia, Z. (2005). Ginseno-
sides compound (shen-fu) attenuates gastrointestinal injury and inhibits 
inflammatory response after cardiopulmonary bypass in patients with 
congenital Heart disease (in Chinese). J Thorac Cardiovasc Surg 130, 
258–264. 
Xiao, Y., Ma, Z., Wang, Y., Tang, H., Zhao, Y., Liang, Q., Tang, X., Xiao, 
C., and Gao, Y. (2013). Study of Shenfu pracparata on the toxicity ef-
fects of antiarrhythmia induced by aconitine (in Chinese). Pharmacol 
Clin Chin Mater Med 29, 12–15. 
Xu, H., Ge, Y., Deng, T., Wang, T., and Zheng, X. (2005). Protective ef-
fect of ginsenoside Rb1 against H2O2-induced apoptosis in neonatal rat 
cardiomyocytes (in Chinese). Chin Pharmacol Bull 21, 803–806. 
Xu, W., and Xu, L. (2012). Clinical study on the treatment of septic shock 
in the combined treatment of the early stage of the treatment (in Chi-
nese). J Emer in Tradit Chin Med 21, 1740–1741. 
Yang, C., Ren, J., Wu, H., and Wang, Y. (2014). Protective effect of gin-
senoside Rb1 on myocardial cell injury induced by ERK1/2 in rats in-
duced by H2O2 (in Chinese). Chin J Integr Med Cardio/Cerebro Dis 12, 
207–209. 
Yang, M., Chen, G., Chen, C., Zhang, Y., and Yan, C. (2008). Effect of 
Ginsenoside Rg1 in promoting myocardial regeneration after myocar-
dial infarction in rats (in Chinese). Chin Heart J 20, 697–707. 
Yang, Q., and Lin, X. (2011). Clinical study on treatment of coronary heart 
failure with ShenFu injection and metoprolol (in Chinese). Hei-
LongJiang Med J 35, 114–115. 
Yang, Y., Wang, H., and Yu, W. (2013). The determination of ginsenoside 
Rg1, ginsenoside Re and ginsenoside Rb3 in Xinyue capsules by HPLC 
(in Chinese). Modern Chin Med 15, 887–890. 
Yao, J., Kong, W., and Jiang, J. (2015). Learning from berberine: treating 
chronic diseases through multiple targets. Sci China Life Sci 58, 
854–859. 
Yi, X., Li, T., Wang, J., Wong, V., Luo, P., Wong, I., Jiang, Z., Liu, L., and 
Zhou, H. (2010). Total ginsenosides increase coronary perfusion flow 
in isolated rat hearts through activation of PI3K/Akt-eNOS signaling. 
Phytomedicine 17, 1006–1015. 
Yu, M., Lv, S., Liu, Z., and Fang, R. (2013). Observation of Shenfu injec-
tion combined with trimetazidine treatment of dilated cardiomyopathy 
heart failure (in Chinese). Chin J Tradit Med Sci and Tech 20, 642–643 
Zeng, Q., Zhan, S., Zhang, W., Sun, X., and Zhong, G. (1997). Research on 
ICa2+ current inhibition effects of ginsenoside Rg1 in myocyte of guin-
ea pig (in Chinese). J N Bethune Univ Med Sci 23, 265–267. 
Zhang, J. (1995). The review and outlook of ginseng research (in Chinese). 
Yao Xue Xue Bao 30, 321–325. 
Zhang, J. Chemistry, Biological Activity and Pharmacokinetics of Panax 
Ginseng Meyer, 2nd ed. (2012). Beijing: Chemical Industry Press. 
Zhang, Q., Chen, Y., Liu F and Chen X. (2013). Ginsenoside-Rg1 pro-
motes angiogenesis in rats with acute myocardial ischemia (in Chi-
nese). J Thir Milit Med Univ 35, 42–45. 
Zhang, Y., and Dong, E. (2014). New insight into vascular homeostasis 
and injury-reconstruction. Sci China Life Sci 57, 739–741. 
Zhang, R., and Liu, Y. (2009). Effects of ginsenoside Rg1 on blood vessel 
regeneration and VEGF expression in rats with acute myocardial in-
farction (in Chinese). Chongqing Med 38, 805–807. 
Zhang, W., Li, L., Zhao, C., Li, X., Zhao, M., and Zhong, G. (2007). Ef-
fects of panaxadiolsaponins monomer Rb1 on action potential and 
L-type calcium channel in ischemic cardiomyocytes (in Chinese). J Ji-
lin Univ (Med Edition) 33, 978–981. 
Zhang, W., Zhang, W., Li, Y., and Zhong, G. (2001).Effect of Rb1 on adult 
rat cardiomyocytes apoptosis (in Chinese). J N Bethune Unv Med Sci 
27, 598–600. 
Zhang, X., Qu, S., Sui, D., Yu, X., and Lv, Z. (2004). Effects of ginseno-
side Rb on blood lipid metabolism and anti-oxidation in hyperlipidemia 
rats (in Chinese). Chin J Chin Mater Med 29, 1085–1088. 
Zhao, H., Feng, J., Lv, D., Xiang, Z., Ma, C., Qin, C., and Zhang, L. 
(2009). Ginsenoside-Rb1 improved cardiac function and inhibited car-
diac remodeling in transgenic mouse model of dilated cardiomyopathy 
(in Chinese). Chin J Compara Med 19, 6–10. 
Zhao, Y. (2014). The content analysis method of ginsenoside-Re in 
Zhenyuan capsules (in Chinese). Chin J Pharma Econo 1, 41–42. 
Zheng, G., Li, J., and Wang, J. (2010). Clinical study on the treatment of 
dilated cardiomyopathy heart failure with the combination of statins 
and ShenFu Injection (in Chinese). Chin J Tradit Med Sci Tech 17, 
482–483. 
Zhou, Q., Jiang, L., Xu, C., Luo, D., Zeng, C., Liu, P., Yue, M., Liu, Y., 
Hu, X., and Hu, H. (2014). Ginsenoside Rg1 inhibits platelet activation 
and arterial thrombosis. Thromb Res 133, 57–65. 
 
Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction 
in any medium, provided the original author(s) and source are credited. 
